Overview

Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)

Status:
Recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

Patient's immune systems are often damaged by chemotherapy or by CLL. Researchers want to learn if giving T-cells (immune cells) that have been expanded and specially processed in the laboratory (activated) will help CLL patients' immune systems recover after chemotherapy. This may help lower the chance of infections. The goal of this clinical research study is to learn if an activated T-cell infusion, when given with or without lenalidomide, can help to restore patients' immune systems when given after chemotherapy (rituximab and fludarabine with cyclophosphamide or bendamustine). The safety of this treatment combination will also be studied. Researchers also want to learn if the activated T-cells may also be able to kill cancer cells.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Bendamustine Hydrochloride
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Lenalidomide
Rituximab
Thalidomide
Vidarabine